Article

Phase III trial uses innovative delivery system to treat DME

Alimera Sciences Inc. and Control Delivery Systems Inc. (CDS) began a phase III clinical trial to study patients with diabetic macular edema (DME) treated using the Medidur implant to deliver fluocinolone acetonide.

The masked, randomized, multicenter study will follow 900 patients in the United States and Europe for 36 months. The Medidur implant, injected through a needle during an in-office procedure, is expected to provide sustained delivery of fluocinolone acetonide to the back of the eye for up to 3 years, according to Alimera Sciences.

"Advanced therapies require innovative methods of delivery, and Medidur fits that model," said Dan Myers, president and chief executive officer of Alimera Sciences, Alpharetta, GA. "The Alimera Sciences team is delighted to reach this critical product development milestone with CDS at such a stage of our company's progression. We anticipate that Medidur technology will allow eye-care professionals to provide their DME patients with an effective and long-lasting therapeutic treatment."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.